{"title":"The prognostic and immune significance of <i>SNHG3</i> in clear cell renal cell carcinoma.","authors":"Cheng Li, Pengnan Hu, Chenglong Fan, Hua Mi","doi":"10.21037/tcr-24-1509","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Long non-coding RNA (lncRNA) small nucleolar RNA host gene 3 (<i>SNHG3</i>) has been reported to be involved in the pathological process of a variety of tumors, including clear cell renal cell carcinoma (ccRCC). However, whether <i>SNHG3</i> can be used as a prognostic biomarker and its correlation with immune infiltration in ccRCC remain unclear, warranting further research. This study aims to explore the relationship between <i>SNHG3</i> and immune infiltration in ccRCC and confirm the potential of <i>SNHG3</i> to predict survival of ccRCC patients.</p><p><strong>Methods: </strong>The Cancer Genome Atlas (TCGA) database was used to assess the expression of <i>SNHG3</i> in ccRCC, evaluate clinicopathological characteristics, assess prognosis, and conduct functional enrichment analysis. The ccRCC microenvironment and immune infiltration were investigated using the Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data (ESTIMATE) and Cell-type Identification By Estimating Relative Subsets Of RNA Transcripts (CIBERSORT) algorithms, respectively. We additionally investigated the relationships between <i>SNHG3</i> and immunological checkpoints. Drug sensitivity of <i>SNHG3</i> was investigated in R. The expression of <i>SNHG3</i> was verified in the Gene Expression Omnibus (GEO) database, ccRCC cell lines, and tissues. Wound healing and Methylthiazolyldiphenyl-tetrazolium bromide (MTT) assays were used to evaluate tumor cell migration and proliferation. Fluorescence in situ hybridization (FISH) assay was conducted to localize <i>SNHG3</i> in ccRCC cells.</p><p><strong>Results: </strong><i>SNHG3</i> expression was significantly upregulated in ccRCC cells and tissues and associated with several clinicopathological features and poor prognosis of ccRCC patients. <i>SNHG3</i> was correlated with immune cells infiltration in ccRCC and exhibited sensitivity to various targeted and chemotherapy drugs. Knockdown of <i>SNHG3</i> significantly reduced the proliferation and migration of ccRCC. FISH results showed that <i>SNHG3</i> was located in the cell nucleus.</p><p><strong>Conclusions: </strong>Overall, this study demonstrates that <i>SNHG3</i> is a prognostic biomarker correlated with immune infiltration in ccRCC.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 2","pages":"1008-1023"},"PeriodicalIF":1.5000,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912088/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tcr-24-1509","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/26 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Long non-coding RNA (lncRNA) small nucleolar RNA host gene 3 (SNHG3) has been reported to be involved in the pathological process of a variety of tumors, including clear cell renal cell carcinoma (ccRCC). However, whether SNHG3 can be used as a prognostic biomarker and its correlation with immune infiltration in ccRCC remain unclear, warranting further research. This study aims to explore the relationship between SNHG3 and immune infiltration in ccRCC and confirm the potential of SNHG3 to predict survival of ccRCC patients.
Methods: The Cancer Genome Atlas (TCGA) database was used to assess the expression of SNHG3 in ccRCC, evaluate clinicopathological characteristics, assess prognosis, and conduct functional enrichment analysis. The ccRCC microenvironment and immune infiltration were investigated using the Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data (ESTIMATE) and Cell-type Identification By Estimating Relative Subsets Of RNA Transcripts (CIBERSORT) algorithms, respectively. We additionally investigated the relationships between SNHG3 and immunological checkpoints. Drug sensitivity of SNHG3 was investigated in R. The expression of SNHG3 was verified in the Gene Expression Omnibus (GEO) database, ccRCC cell lines, and tissues. Wound healing and Methylthiazolyldiphenyl-tetrazolium bromide (MTT) assays were used to evaluate tumor cell migration and proliferation. Fluorescence in situ hybridization (FISH) assay was conducted to localize SNHG3 in ccRCC cells.
Results: SNHG3 expression was significantly upregulated in ccRCC cells and tissues and associated with several clinicopathological features and poor prognosis of ccRCC patients. SNHG3 was correlated with immune cells infiltration in ccRCC and exhibited sensitivity to various targeted and chemotherapy drugs. Knockdown of SNHG3 significantly reduced the proliferation and migration of ccRCC. FISH results showed that SNHG3 was located in the cell nucleus.
Conclusions: Overall, this study demonstrates that SNHG3 is a prognostic biomarker correlated with immune infiltration in ccRCC.
期刊介绍：
Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients'' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
